ClinicalTrials.gg
CompletedNCT01026038Updated Feb 8, 2012Results posted

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine in 13-valent Pneumococcal Vaccine, Immunization and Safety, sponsored by Pfizer. Completed at 25 sites in France. Open to participants aged 3 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-08.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
263
Allocation
Non-randomized
Ages
3 Years and older
Sex
All
01

Study summary

This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678). In this study, participants will receive an additional dose of 13-valent pneumococcal conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the antibody response by measuring any remaining pneumococcal antibodies since the previous study. This study will also evaluate the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine when administered at least 24 months after the last dose of pneumococcal conjugate vaccine.

02

Conditions studied

  • 13-valent Pneumococcal Vaccine
  • Immunization
  • Safety
  • Antibody Response

Keywords

  • Pneumococcal vaccine 13-valent
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects at least 3 years of age, who received all 4 assigned doses of pneumococcal conjugate vaccine and completed Study 6096A1-008-EU (NCT00366678) for at least 24 months

Exclusion criteria

Exclusion Criteria:

  • Vaccination with any licensed or pneumococcal vaccine since completion of Study 6096A1-008-EU(NCT00366678).
  • History of culture-proven invasive disease caused by S pneumoniae since the completion of Study 6096A1-008-EU (NCT00366678).
  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • to vaccination
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
263 participants (actual)

Study arms

  • Experimental
    1

    1 dose (0.5 mL), IM of 13vPnC vaccine.

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine

    Antibody GMC as measured by microgram/millilitre (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

    Time frame: One month after vaccination

  2. Percentage of Participants With Prespecified Local Reactions

    Local reactions (redness, swelling and pain) were reported using electronic diary. Redness and swelling were recorded in caliper units (range 1 to 14+), each caliper unit represented 0.5 cm. Categorized as any, absent (no redness or swelling present; 0 caliper units), mild (0.5 to 2.0 cm; 1 to 4 caliper units); moderate (2.5 to 7.0 cm; 5 to 14 caliper units); or severe (\>7.0 cm; \>14 caliper units). Pain was categorized as any, mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity. Participants may be reported in more than 1 category.

    Time frame: Seven days after vaccination

  3. Percentage of Participants With Prespecified Systemic Events

    Systemic events (any fever \>= 38 degree celsius \[C\], vomiting, diarrhea, and fatigue) were reported using electronic diary. Fever categorized as \>=38 to \<=39 degree C; \>39 to \<=40 degree C; \>40 degree C. Vomiting: mild (1-2 times/day ); moderate (\>2 times/day); severe (requires intravenous hydration). Diarrhea: mild (2-3 loose stools/day); moderate (4-5 stools/day); severe (\>=6 loose stools/day). Fatigue: mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity). Participants may be reported in more than 1 category.

    Time frame: Seven days after vaccination

Secondary outcomes

  1. Serotype-specific Pneumococcal IgG GMC Prior to Single Dose of 13vPnC Vaccine

    IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG enzymelinked immunosorbent assay (ELISA). CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Up to 7 days before vaccination

  2. Serotype-specific Pneumococcal IgG GMC at 4 to 7 Days After the Single Dose of 13vPnC Vaccine

    IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG ELISA. CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Four to seven days after vaccination

  3. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Prior to Single Dose of 13vPnC Vaccine

    Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: Up to 7 days before vaccination

  4. Serotype-specific OPA GMTs 1 Month After Single Dose of 13vPnC Vaccine

    Serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

    Time frame: One month after vaccination

  5. Percentage of Participants With at Least 1/8 Serotype-specific OPA GMTs After Single Dose of 13vPnC Vaccine

    Percentage of participants with at least 1/8 serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) determined in the blood samples of all participants.

    Time frame: One month after vaccination

  6. Percentage of Participants With at Least 1/2048 OPA GMTs for Serotype 7F After Single Dose of 13vPnC Vaccine

    Percentage of participants with at least 1/2048 serotype-specific pneumococcal OPA GMTs for serotype 7F determined in the blood samples of all participants.

    Time frame: One month after vaccination

07

Results

Posted Feb 8, 2012

Participant flow

Participant flow — Overall Study
Milestone13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
Started1306567
Completed1296467
Not completed110
Withdrew: Lost to follow-up110

Outcome measures

PrimarySerotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine

Antibody GMC as measured by microgram/millilitre (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.

Time frame:
One month after vaccination
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine
mcg/mL13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
410.34 (8.94 to 11.97)12.79 (10.00 to 16.35)8.98 (6.98 to 11.56)
6B31.62 (27.02 to 37.01)51.07 (38.65 to 67.49)35.38 (27.25 to 45.93)
9V6.76 (5.90 to 7.73)6.50 (5.31 to 7.95)6.19 (5.04 to 7.61)
1421.55 (18.41 to 25.24)21.15 (16.89 to 26.48)20.73 (16.45 to 26.12)
18C4.56 (3.93 to 5.29)6.12 (4.89 to 7.65)5.35 (4.27 to 6.71)
19F16.59 (13.57 to 20.28)12.07 (9.35 to 15.59)15.09 (11.17 to 20.39)
23F8.68 (7.50 to 10.03)10.87 (8.30 to 14.22)9.10 (7.34 to 11.28)
110.72 (9.17 to 12.52)2.96 (2.45 to 3.59)20.69 (16.14 to 26.53)
31.81 (1.46 to 2.23)1.60 (1.19 to 2.17)2.07 (1.66 to 2.59)
510.00 (8.63 to 11.58)2.86 (2.37 to 3.46)19.20 (14.93 to 24.70)
6A23.09 (19.50 to 27.33)14.38 (10.53 to 19.64)18.60 (13.87 to 24.93)
7F8.23 (7.11 to 9.52)5.04 (4.16 to 6.11)8.02 (6.66 to 9.67)
19A17.10 (14.54 to 20.11)8.58 (6.70 to 10.99)16.46 (13.42 to 20.19)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.81 · 95% CI 0.61 to 1.07
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.15 · 95% CI 0.87 to 1.52
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.42 · 95% CI 1.03 to 1.96
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.62 · 95% CI 0.46 to 0.84
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.89 · 95% CI 0.66 to 1.20
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.44 · 95% CI 1.02 to 2.04
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.04 · 95% CI 0.82 to 1.32
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.09 · 95% CI 0.86 to 1.39
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.05 · 95% CI 0.79 to 1.39
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.02 · 95% CI 0.77 to 1.34
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.04 · 95% CI 0.79 to 1.37
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.02 · 95% CI 0.74 to 1.40
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.75 · 95% CI 0.57 to 0.97
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.85 · 95% CI 0.65 to 1.11
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmcratio: 1.14 · 95% CI 0.84 to 1.56
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.37 · 95% CI 0.97 to 1.94
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.10 · 95% CI 0.78 to 1.55
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.80 · 95% CI 0.54 to 1.19
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.80 · 95% CI 0.61 to 1.05
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.95 · 95% CI 0.73 to 1.25
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.19 · 95% CI 0.87 to 1.64
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 3.62 · 95% CI 2.76 to 4.74
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.52 · 95% CI 0.40 to 0.68
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.14 · 95% CI 0.10 to 0.20
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.13 · 95% CI 0.80 to 1.59
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.87 · 95% CI 0.62 to 1.23
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.77 · 95% CI 0.52 to 1.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 3.49 · 95% CI 2.68 to 4.54
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.52 · 95% CI 0.40 to 0.68
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.15 · 95% CI 0.11 to 0.20
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.61 · 95% CI 1.15 to 2.23
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.24 · 95% CI 0.89 to 1.72
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.77 · 95% CI 0.53 to 1.13
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.63 · 95% CI 1.28 to 2.08
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.03 · 95% CI 0.81 to 1.30
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.63 · 95% CI 0.47 to 0.83
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.99 · 95% CI 1.51 to 2.63
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.04 · 95% CI 0.79 to 1.37
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.52 · 95% CI 0.38 to 0.72
PrimaryPercentage of Participants With Prespecified Local Reactions

Local reactions (redness, swelling and pain) were reported using electronic diary. Redness and swelling were recorded in caliper units (range 1 to 14+), each caliper unit represented 0.5 cm. Categorized as any, absent (no redness or swelling present; 0 caliper units), mild (0.5 to 2.0 cm; 1 to 4 caliper units); moderate (2.5 to 7.0 cm; 5 to 14 caliper units); or severe (\>7.0 cm; \>14 caliper units). Pain was categorized as any, mild: does not interfere with activity; moderate: interferes with activity; severe: prevents daily activity. Participants may be reported in more than 1 category.

Time frame:
Seven days after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Prespecified Local Reactions
Percentage of Participants13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
Pain: Any (n= 112, 52, 53)55.455.864.2
Pain: Mild (n= 109, 51, 51)50.549.056.9
Pain: Moderate (n= 95, 47, 48)17.925.520.8
Pain: Severe (n= 90, 43, 45)1.12.32.2
Swelling: Any (101, 48, 47)39.641.727.7
Swelling: Mild (n= 96, 48, 47)28.135.423.4
Swelling: Moderate (n= 97, 44, 46)24.720.510.9
Swelling: Severe (n= 90, 43, 45)0.02.30.0
Redness: Any (n= 105, 50, 50)48.654.046.0
Redness: Mild (n= 101, 49, 48)38.640.837.5
Redness: Moderate (n= 95, 45, 47)22.131.117.0
Redness: Severe (n= 90, 43, 45)0.02.30.0
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = >0.990
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.429
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.314
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = >0.990
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.552
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.499
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.376
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.633
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.658
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.544
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.859
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.197
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.198
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.443
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.261
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.687
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.671
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.253
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.074
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.323
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.489
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.607
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.549
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.864
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.859
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.836
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.297
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.145
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.517
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.323
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.489
PrimaryPercentage of Participants With Prespecified Systemic Events

Systemic events (any fever \>= 38 degree celsius \[C\], vomiting, diarrhea, and fatigue) were reported using electronic diary. Fever categorized as \>=38 to \<=39 degree C; \>39 to \<=40 degree C; \>40 degree C. Vomiting: mild (1-2 times/day ); moderate (\>2 times/day); severe (requires intravenous hydration). Diarrhea: mild (2-3 loose stools/day); moderate (4-5 stools/day); severe (\>=6 loose stools/day). Fatigue: mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity). Participants may be reported in more than 1 category.

Time frame:
Seven days after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants With Prespecified Systemic Events
Percentage of Participants13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
Fever >=38 to <=39 degree C (n= 93, 49, 46)15.128.619.6
Fever >39 to <=40 degree C (n= 92, 43, 46)2.24.72.2
Fever >40 degree C (n= 90, 43, 45)0.00.02.2
Vomiting: Any (n= 91, 44, 45)3.39.16.7
Vomiting: Mild (n= 91, 44, 45)3.39.16.7
Vomiting: Moderate (n= 90, 43, 45)0.00.00.0
Vomiting: Severe (n= 90, 43, 45)0.00.00.0
Diarrhea: Any (n= 90, 45, 47)8.917.88.5
Diarrhea: Mild (n= 90, 45, 47)8.917.88.5
Diarrhea: Moderate (n= 90, 43, 45)1.10.00.0
Diarrhea: Severe (n= 90, 43, 45)0.00.00.0
Fatigue: Any (n= 103, 54, 48)40.851.931.3
Fatigue: Mild (n= 100, 49, 48)34.034.720.8
Fatigue: Moderate (n= 96, 49, 46)16.730.615.2
Fatigue: Severe (n= 92, 43, 45)3.32.32.2
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.075
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.345
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.628
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.592
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.608
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.333
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.215
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.714
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.397
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.215
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.714
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.397
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.161
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.226
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.161
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.226
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.237
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.045
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.285
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = >0.990
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.174
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.125
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = 0.058
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = 0.092
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Fisher Exact · p = >0.990
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Fisher Exact · p = >0.990
SecondarySerotype-specific Pneumococcal IgG GMC Prior to Single Dose of 13vPnC Vaccine

IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG enzymelinked immunosorbent assay (ELISA). CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Up to 7 days before vaccination
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal IgG GMC Prior to Single Dose of 13vPnC Vaccine
mcg/mL13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
40.17 (0.15 to 0.21)0.23 (0.18 to 0.30)0.18 (0.15 to 0.22)
6B2.86 (2.35 to 3.48)4.10 (2.96 to 5.68)3.21 (2.37 to 4.36)
9V0.72 (0.60 to 0.85)0.92 (0.72 to 1.17)0.71 (0.58 to 0.87)
140.77 (0.61 to 0.98)0.74 (0.52 to 1.06)0.59 (0.42 to 0.83)
18C0.21 (0.17 to 0.25)0.36 (0.28 to 0.47)0.23 (0.18 to 0.28)
19F2.22 (1.67 to 2.95)2.11 (1.43 to 3.11)1.44 (1.04 to 2.02)
23F1.26 (1.00 to 1.58)1.56 (1.19 to 2.05)1.18 (0.92 to 1.52)
10.35 (0.29 to 0.43)0.14 (0.09 to 0.20)0.28 (0.23 to 0.34)
30.50 (0.35 to 0.71)0.47 (0.29 to 0.75)0.42 (0.30 to 0.58)
51.28 (1.07 to 1.53)1.12 (0.89 to 1.41)1.41 (1.19 to 1.67)
6A4.05 (3.25 to 5.04)1.89 (1.50 to 2.38)2.47 (1.91 to 3.21)
7F0.65 (0.55 to 0.78)0.21 (0.15 to 0.30)0.77 (0.62 to 0.96)
19A6.16 (4.88 to 7.79)3.38 (2.60 to 4.41)4.63 (3.43 to 6.26)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.75 · 95% CI 0.56 to 1.00
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.96 · 95% CI 0.73 to 1.28
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.29 · 95% CI 0.92 to 1.79
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.70 · 95% CI 0.49 to 1.00
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.89 · 95% CI 0.62 to 1.27
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.27 · 95% CI 0.84 to 1.94
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.78 · 95% CI 0.58 to 1.03
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.01 · 95% CI 0.76 to 1.33
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.29 · 95% CI 0.93 to 1.80
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.04 · 95% CI 0.69 to 1.58
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.30 · 95% CI 0.86 to 1.97
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.25 · 95% CI 0.77 to 2.03
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.58 · 95% CI 0.42 to 0.78
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.91 · 95% CI 0.67 to 1.23
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.58 · 95% CI 1.11 to 2.25
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.05 · 95% CI 0.66 to 1.68
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.54 · 95% CI 0.97 to 2.44
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.46 · 95% CI 0.85 to 2.51
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.80 · 95% CI 0.56 to 1.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.06 · 95% CI 0.74 to 1.52
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.32 · 95% CI 0.87 to 2.01
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 2.59 · 95% CI 1.80 to 3.73
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.26 · 95% CI 0.88 to 1.79
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.49 · 95% CI 0.32 to 0.74
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.06 · 95% CI 0.61 to 1.87
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.19 · 95% CI 0.68 to 2.09
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.12 · 95% CI 0.59 to 2.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.15 · 95% CI 0.87 to 1.52
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.91 · 95% CI 0.69 to 1.20
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.79 · 95% CI 0.57 to 1.10
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 2.14 · 95% CI 1.52 to 3.02
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.64 · 95% CI 1.16 to 2.30
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.76 · 95% CI 0.51 to 1.14
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 3.11 · 95% CI 2.23 to 4.33
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.84 · 95% CI 0.61 to 1.17
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.27 · 95% CI 0.19 to 0.40
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratrio: 1.82 · 95% CI 1.25 to 2.66
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.33 · 95% CI 0.91 to 1.94
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.73 · 95% CI 0.47 to 1.13
SecondarySerotype-specific Pneumococcal IgG GMC at 4 to 7 Days After the Single Dose of 13vPnC Vaccine

IgG GMC to the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a standardized anti-pneumococcal IgG ELISA. CIs for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Four to seven days after vaccination
Reported as:
Geometric mean · mcg/mL
Serotype-specific Pneumococcal IgG GMC at 4 to 7 Days After the Single Dose of 13vPnC Vaccine
mcg/mL13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
42.96 (1.67 to 5.24)4.66 (2.01 to 10.82)3.85 (1.70 to 8.74)
6B17.78 (12.50 to 25.30)19.15 (8.84 to 41.48)16.26 (8.10 to 32.66)
9V3.49 (2.39 to 5.09)3.15 (1.75 to 5.66)3.20 (1.86 to 5.50)
145.55 (3.32 to 9.30)5.67 (2.29 to 13.99)4.52 (2.14 to 9.52)
18C2.31 (1.36 to 3.91)3.34 (1.66 to 6.72)2.51 (1.33 to 4.73)
19F11.70 (7.21 to 19.00)6.88 (2.98 to 15.86)8.51 (4.38 to 16.55)
23F5.24 (3.49 to 7.87)5.82 (2.97 to 11.40)6.28 (3.50 to 11.26)
14.24 (2.48 to 7.26)0.56 (0.27 to 1.18)8.00 (3.51 to 18.23)
31.24 (0.79 to 1.95)1.12 (0.56 to 2.25)1.24 (0.90 to 1.72)
56.00 (4.16 to 8.66)1.43 (0.99 to 2.06)9.81 (5.29 to 18.19)
6A13.86 (9.69 to 19.83)4.46 (2.18 to 9.12)7.37 (3.95 to 13.78)
7F3.55 (2.35 to 5.36)1.23 (0.69 to 2.21)3.08 (1.72 to 5.51)
19A13.07 (9.63 to 17.74)5.09 (3.17 to 8.19)10.50 (7.12 to 15.50)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.63 · 95% CI 0.23 to 1.76
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.77 · 95% CI 0.30 to 1.99
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.21 · 95% CI 0.38 to 3.86
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.93 · 95% CI 0.43 to 1.99
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.09 · 95% CI 0.54 to 2.22
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.18 · 95% CI 0.50 to 2.79
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.11 · 95% CI 0.56 to 2.19
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.09 · 95% CI 0.58 to 2.06
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.98 · 95% CI 0.46 to 2.13
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.98 · 95% CI 0.38 to 2.55
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.23 · 95% CI 0.50 to 3.00
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.25 · 95% CI 0.42 to 3.72
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.69 · 95% CI 0.29 to 1.68
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.92 · 95% CI 0.40 to 2.10
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.33 · 95% CI 0.49 to 3.64
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.70 · 95% CI 0.70 to 4.12
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.37 · 95% CI 0.60 to 3.14
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.81 · 95% CI 0.30 to 2.21
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 0.90 · 95% CI 0.43 to 1.89
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.83 · 95% CI 0.42 to 1.67
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.93 · 95% CI 0.40 to 2.16
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 7.53 · 95% CI 2.86 to 19.78
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.53 · 95% CI 0.22 to 1.31
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.07 · 95% CI 0.02 to 0.21
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 1.11 · 95% CI 0.53 to 2.30
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.00 · 95% CI 0.50 to 1.97
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.90 · 95% CI 0.39 to 2.07
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 4.20 · 95% CI 2.18 to 8.09
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.61 · 95% CI 0.33 to 1.13
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.15 · 95% CI 0.07 to 0.31
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 3.11 · 95% CI 1.51 to 6.40
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.88 · 95% CI 0.96 to 3.69
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.60 · 95% CI 0.27 to 1.37
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 2.88 · 95% CI 1.39 to 5.98
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.15 · 95% CI 0.58 to 2.28
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.40 · 95% CI 0.17 to 0.92
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmc ratio: 2.57 · 95% CI 1.50 to 4.39
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 1.24 · 95% CI 0.75 to 2.05
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmc ratio: 0.48 · 95% CI 0.26 to 0.89
SecondarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Prior to Single Dose of 13vPnC Vaccine

Pneumococcal OPA GMTs for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a microcolony OPA (mcOPA) assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
Up to 7 days before vaccination
Reported as:
Geometric mean · Geometric mean titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Prior to Single Dose of 13vPnC Vaccine
Geometric mean titers13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
4 (n= 40, 14, 19)8 (4.4 to 13.1)46 (7.8 to 268.5)45 (10.6 to 190.6)
6B (n= 38, 16, 21)245 (92.6 to 646.9)247 (49.1 to 1241.8)332 (84.4 to 1304.3)
9V (n= 40, 18, 21)43 (16.3 to 111.9)36 (8.6 to 149.1)52 (14.6 to 187.8)
14 (n= 39, 16, 20)98 (39.7 to 242.9)40 (9.2 to 174.2)49 (14.4 to 163.9)
18C (n= 42, 17, 19)14 (6.9 to 27.7)76 (15.7 to 363.0)28 (7.2 to 109.7)
19F (n= 43, 17, 21)48 (20.8 to 112.5)49 (13.0 to 182.6)40 (14.0 to 112.5)
23F (n= 43, 16, 21)52 (22.5 to 120.3)61 (13.1 to 284.3)178 (54.6 to 578.7)
1 (n= 44, 18, 22)6 (4.5 to 7.5)5 (3.4 to 6.5)10 (6.9 to 15.0)
3 (n= 42, 17, 21)20 (11.8 to 34.6)10 (4.4 to 22.2)18 (12.1 to 28.0)
5 (n= 44, 18, 22)4 (NA to NA)4 (NA to NA)4 (3.6 to 5.6)
6A (n= 44, 16, 21)170 (72.8 to 395.5)10 (3.4 to 31.4)75 (22.3 to 253.9)
7F (n= 39, 16, 21)60 (22.5 to 157.8)47 (10.0 to 225.2)389 (112.0 to 1351.1)
19A (n= 41, 18, 20)118 (58.2 to 239.7)25 (7.4 to 82.0)124 (46.4 to 330.2)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.04 to 0.73
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.04 to 0.64
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.19 to 5.46
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.17 to 5.85
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.15 to 3.72
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.10 to 5.37
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.2 · 95% CI 0.23 to 6.25
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.17 to 3.92
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.11 to 4.43
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 2.4 · 95% CI 0.48 to 12.35
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 2.0 · 95% CI 0.45 to 9.05
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.13 to 5.14
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.04 to 0.80
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.12 to 2.03
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 2.7 · 95% CI 0.48 to 14.92
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.23 to 4.36
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.2 · 95% CI 0.31 to 4.84
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.2 · 95% CI 0.23 to 6.65
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.17 to 4.17
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.3 · 95% CI 0.07 to 1.24
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.3 · 95% CI 0.06 to 2.08
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.3 · 95% CI 0.79 to 1.97
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.6 · 95% CI 0.38 to 0.88
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.27 to 0.77
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 2.0 · 95% CI 0.85 to 4.90
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.1 · 95% CI 0.49 to 2.48
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.20 to 1.45
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.87 to 1.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.79 to 1.03
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.76 to 1.06
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 16.5 · 95% CI 3.56 to 76.14
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 2.3 · 95% CI 0.56 to 9.06
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.1 · 95% CI 0.02 to 0.78
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.3 · 95% CI 0.22 to 7.07
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.03 to 0.74
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.1 · 95% CI 0.02 to 0.84
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 4.8 · 95% CI 1.35 to 16.98
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.28 to 3.23
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.05 to 0.85
SecondarySerotype-specific OPA GMTs 1 Month After Single Dose of 13vPnC Vaccine

Serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using mcOPA assay. CIs for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.

Time frame:
One month after vaccination
Reported as:
Geometric mean · Geometric mean titers
Serotype-specific OPA GMTs 1 Month After Single Dose of 13vPnC Vaccine
Geometric mean titers13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
4 (n= 117, 53, 55)5465 (4698.9 to 6356.4)5208 (4301.7 to 6304.2)5487 (4236.9 to 7106.4)
6B (n= 117, 57, 56)6684 (5638.4 to 7924.4)10042 (7697.5 to 13101.6)8983 (7006.9 to 11516.8)
9V (n= 116, 54, 55)5120 (4456.1 to 5882.6)4052 (3291.0 to 4989.7)5221 (4110.4 to 6630.7)
14 (n= 115, 54, 55)2780 (2374.7 to 3254.6)3079 (2450.6 to 3869.4)2979 (2232.9 to 3973.4)
18C (n= 117, 54, 57)7711 (6589.6 to 9023.3)7091 (5655.9 to 8889.9)8431 (6740.3 to 10545.7)
19F (n= 118, 57, 57)1319 (1030.5 to 1689.5)1721 (1316.8 to 2250.3)1914 (1350.6 to 2712.5)
23F (n= 118, 53, 56)2427 (2063.6 to 2855.0)2411 (1792.5 to 3242.4)2673 (2091.2 to 3417.3)
1 (n= 119, 56, 57)613 (525.2 to 715.7)197 (161.4 to 239.4)1212 (968.0 to 1516.9)
3 (n= 118, 56, 58)244 (214.7 to 276.4)173 (139.5 to 214.5)291 (239.4 to 353.7)
5 (n= 118, 55, 54)455 (358.7 to 537.9)390 (281.2 to 541.8)728 (545.0 to 972.2)
6A (n= 117, 55, 55)5580 (4593.6 to 6777.0)5596 (4276.6 to 7321.2)5982 (4450.7 to 8041.1)
7F (n= 118, 56, 54)4323 (3794.4 to 4925.1)8048 (6500.9 to 9962.2)4056 (3092.2 to 5321.2)
19A (n= 116, 53, 54)1212 (1048.1 to 1400.7)1249 (956.5 to 1632.3)1568 (1249.7 to 1966.1)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.80 to 1.38
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.76 to 1.30
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.69 to 1.30
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.49 to 0.90
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.55 to 1.01
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.1 · 95% CI 0.79 to 1.59
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.3 · 95% CI 0.98 to 1.63
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.76 to 1.27
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.58 to 1.05
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.67 to 1.21
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.70 to 1.25
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.73 to 1.46
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.1 · 95% CI 0.83 to 1.43
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.70 to 1.20
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.61 to 1.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.51 to 1.15
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.7 · 95% CI 0.46 to 1.03
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.56 to 1.44
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.74 to 1.37
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.67 to 1.23
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.63 to 1.29
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 3.1 · 95% CI 2.40 to 4.06
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.39 to 0.66
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.2 · 95% CI 0.12 to 0.22
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.4 · 95% CI 1.11 to 1.78
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.66 to 1.06
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.6 · 95% CI 0.45 to 0.78
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.2 · 95% CI 0.84 to 1.62
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.6 · 95% CI 0.45 to 0.87
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.36 to 0.79
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.71 to 1.40
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.66 to 1.31
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.9 · 95% CI 0.63 to 1.39
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 0.5 · 95% CI 0.41 to 0.70
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 1.1 · 95% CI 0.82 to 1.38
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 2.0 · 95% CI 1.46 to 2.69
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Gmt ratio: 1.0 · 95% CI 0.74 to 1.28
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.59 to 1.02
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Gmt ratio: 0.8 · 95% CI 0.58 to 1.10
SecondaryPercentage of Participants With at Least 1/8 Serotype-specific OPA GMTs After Single Dose of 13vPnC Vaccine

Percentage of participants with at least 1/8 serotype-specific pneumococcal OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) determined in the blood samples of all participants.

Time frame:
One month after vaccination
Reported as:
Number · Percentage of Participants

No measurements were reported for this outcome.

SecondaryPercentage of Participants With at Least 1/2048 OPA GMTs for Serotype 7F After Single Dose of 13vPnC Vaccine

Percentage of participants with at least 1/2048 serotype-specific pneumococcal OPA GMTs for serotype 7F determined in the blood samples of all participants.

Time frame:
One month after vaccination
Reported as:
Number · Percentage of Participants

No measurements were reported for this outcome.

Post-hocPercentage of Participants Achieving OPA GMTs With at Least Lower Limit of Quantification (LLOQ) 1 Month After Single Dose of 13vPnC Vaccine

Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using mcOPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43; Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; Pn23F, 13. LOD established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5\*LOD for analysis.

Time frame:
One month after vaccination
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving OPA GMTs With at Least Lower Limit of Quantification (LLOQ) 1 Month After Single Dose of 13vPnC Vaccine
Percentage of Participants13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
4 (n= 117, 53, 55)100.0 (96.9 to 100.0)100.0 (93.3 to 100.0)100.0 (93.5 to 100.0)
6B (n= 117, 57, 56)100.0 (96.9 to 100.0)100.0 (93.7 to 100.0)100.0 (93.6 to 100.0)
9V (n= 116, 54, 55)100.0 (96.9 to 100.0)100.0 (93.4 to 100.0)100.0 (93.5 to 100.0)
14 (n= 115, 54, 55)100.0 (96.8 to 100.0)100.0 (93.4 to 100.0)100.0 (93.5 to 100.0)
18C (n= 117, 54, 57)100.0 (96.9 to 100.0)100.0 (93.4 to 100.0)100.0 (93.7 to 100.0)
19F (n= 118, 57, 57)98.3 (94.0 to 99.8)100.0 (93.7 to 100.0)98.2 (90.6 to 100.0)
23F (n= 118, 53, 56)100.0 (96.9 to 100.0)100.0 (93.3 to 100.0)100.0 (93.6 to 100.0)
1 (n= 119, 56, 57)100.0 (96.9 to 100.0)100.0 (93.6 to 100.0)100.0 (93.7 to 100.0)
3 (n= 118, 56, 58)100.0 (96.9 to 100.0)98.2 (90.4 to 100.0)100.0 (93.8 to 100.0)
5 (n= 118, 55, 54)99.2 (95.4 to 100.0)96.4 (87.5 to 99.6)100.0 (93.4 to 100.0)
6A (n= 117, 55, 55)100.0 (96.9 to 100.0)100.0 (93.5 to 100.0)100.0 (93.5 to 100.0)
7F (n= 118, 56, 54)100.0 (96.9 to 100.0)100.0 (93.6 to 100.0)100.0 (93.4 to 100.0)
19A (n= 116, 53, 54)100.0 (96.9 to 100.0)100.0 (93.3 to 100.0)100.0 (93.4 to 100.0)
Statistical analysis
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.5 to 6.7
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.5
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.8 to 6.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.7 to 6.3
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.4
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.4 to 6.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.5
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.7 to 6.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.7 to 6.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.7 to 6.5
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.7 to 6.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.7 to 6.3
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.6 to 6.4
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: -1.7 · 95% CI -6.2 to 4.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.1 · 95% CI -4.8 to 7.5
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 1.8 · 95% CI -4.8 to 9.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.5 to 6.7
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.4
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.7 to 6.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.5 to 6.4
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.3
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.5 to 6.3
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 1.8 · 95% CI -1.7 to 9.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.7 to 6.2
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: -1.8 · 95% CI -9.6 to 4.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 2.8 · 95% CI -2.0 to 11.3
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: -0.8 · 95% CI -4.9 to 5.6
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: -3.6 · 95% CI -12.5 to 3.2
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.5
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.5
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.6 to 6.6
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.4
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.5 to 6.6
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.5 to 6.7
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/7vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.7
  • 13vPnC/13vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -3.6 to 6.6
  • 7vPnC/7vPnC/13vPnC vs 7vPnC/13vPnC/13vPnC · Percent difference: 0.0 · 95% CI -6.8 to 6.6

Adverse events

Collected over AEs/SAEs: recorded from signing of informed consent form to completion of study (28-42 days post 13vPnC). Participants recorded prespecified AEs in electronic diary:local reactions; systemic events; use of antipyretic medication (Day 1-Day 7 post 13vPnC).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC/13vPnC/13vPnC—0/130 (0%)82/130 (63.1%)
7vPnC/7vPnC/13vPnC—0/64 (0%)36/64 (56.3%)
7vPnC/13vPnC/13vPnC—0/64 (0%)39/64 (60.9%)
Most frequent other events
Showing 10 of 43
Most frequent other events
Event13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnC
Pain (Any)Skin and subcutaneous tissue disorders62/11229/5234/53
Pain (Mild)Skin and subcutaneous tissue disorders55/10925/5129/51
Redness (Any)Skin and subcutaneous tissue disorders51/10527/5023/50
Fatigue (Any)General disorders42/10328/5415/48
Swelling (Any)Skin and subcutaneous tissue disorders40/10120/4813/47
Redness (Mild)Skin and subcutaneous tissue disorders39/10120/4918/48
Swelling (Mild)Skin and subcutaneous tissue disorders27/9617/4811/47
Fatigue (Mild)General disorders34/10017/4910/48
Redness (Moderate)Skin and subcutaneous tissue disorders21/9514/458/47
Fatigue (Moderate)General disorders16/9615/497/46

Baseline characteristics

Age Continuous
Age Continuous(Years)13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnCTotal
Mean3.4 ± 0.253.4 ± 0.243.5 ± 0.253.4 ± 0.25
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC/13vPnC/13vPnC7vPnC/7vPnC/13vPnC7vPnC/13vPnC/13vPnCTotal
Female702940139
Male603627123
08

Study locations

25 sites
  • Pfizer Investigational Site
    Ancenis, 44150, France
  • Pfizer Investigational Site
    Bondues, 59910, France
  • Pfizer Investigational Site
    Brest, 29200, France
  • Pfizer Investigational Site
    Chalons En Champagne, 51100, France
  • Pfizer Investigational Site
    Draguignan, 83300, France
  • Pfizer Investigational Site
    Ecully, 69130, France
  • Pfizer Investigational Site
    Essey Les Nancy, 54270, France
  • Pfizer Investigational Site
    Floirac, 33270, France
  • Pfizer Investigational Site
    Garges Les Gonesses, 95140, France
  • Pfizer Investigational Site
    Joue Les Tours, 37300, France
  • Pfizer Investigational Site
    Le Havre, 76600, France
  • Pfizer Investigational Site
    Lingolsheim, 67380, France
  • Pfizer Investigational Site
    Lyon, 69007, France
  • Pfizer Investigational Site
    Maromme, 76150, France
  • Pfizer Investigational Site
    Moutiers, 73600, France
  • Pfizer Investigational Site
    Nancy, 54000, France
  • Pfizer Investigational Site
    Nice, 06300, France
  • Pfizer Investigational Site
    Olonne Sur Mer, 85340, France
  • Pfizer Investigational Site
    Strasbourg, 67000, France
  • Pfizer Investigational Site
    Strasbourg, 67100, France
  • Pfizer Investigational Site
    Talence, 33400, France
  • Pfizer Investigational Site
    Thionville, 57100, France
  • Pfizer Investigational Site
    Tours, 37000, France
  • Pfizer Investigational Site
    Villers Les Nancy, 54600, France
  • Pfizer Investigational Site
    Vitry Sur Seine, 94400, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 4, 2009
Start
Apr 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Feb 8, 2012
Last update
Feb 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01026038
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Apr 2010
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Feb 8, 2012
Last update
Feb 8, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion